Hanmi Pharmaceutical Co., Ltd.
KKRX:128940361,500.00
KRW
-9,000.00
(-2.43%)
ISIN
KR7128940004
Return %
Stock
S&P 500
1Y
4.93
14.39
3Y
34.57
81.42
5Y
40.27
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Sang-Yeon Hwang
- Full Time Employees
- 2,382
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 214 Muha-ro Hwaseong-si GY South Korea 18536
- IPO Date
- Jul 30, 2010
- Website
- hanmipharm.com
- Similar Companies
- Business
- Hanmi Pharm. Co., Ltd. (128940.KS) operates as a research-driven biopharmaceutical company focused on the research, development, manufacture, and sale of innovative medicines addressing unmet medical needs in areas including oncology, metabolic disorders such as obesity and diabetes, autoimmune conditions, and rare diseases. The company offers a diverse portfolio of branded pharmaceutical products such as Gugutams, a urological combination therapy for obstructive prostatic growth and erectile dysfunction; Rosuzet, a fixed-dose combination treatment for hyperlipidemia; hypertension therapies including Amodipin and Amosartan; antibiotics; vitamins; raw material drugs; intestinal tonics; cough medicines like Etanjing; gastrointestinal treatments such as Mechanang; and pediatric digestive supplements like Mami Ai; alongside soft capsules processed for other firms and a pipeline of approximately 30 candidates leveraging proprietary platforms like LAPSCOVERY for long-acting formulations and oral delivery technologies. Hanmi Pharm. conducts operations primarily in South Korea, with commercial presence and exports extending to China, Japan, the United States, the Middle East and North Africa (MENA) region, and other international markets. Founded in 1973 by pharmacist Sung-ki Lim and headquartered in Hwaseong-si, South Korea, with additional facilities in Seoul's Songpa-gu and a Beijing research center, the company employs around 2,343 personnel under CEO Jae-Hyun Park and maintains R&D investment approximating 20% of sales. In recent strategic developments, Hanmi Pharm. enters an exclusive licensing agreement with Tabuk Pharmaceuticals in October 2024 to commercialize urology treatments and anticancer biopharmaceuticals in the MENA region, including initial products like Rosuzet and Gugutams, with options for technology transfer and localized manufacturing. The company secures a global licensing and collaboration deal with Gilead Sciences in September 2025 for an oral delivery platform compound, affirming its formulation expertise. Further, Hanmi Pharm. extends financial support to Aptose Biosciences, advancing US$8.5 million under a June 2025 facility agreement and participating in prior financings amid Aptose's arrangement for potential acquisition. These partnerships, alongside ongoing collaborations such as with MEDIC Life Sciences for cancer biomarkers, bolster Hanmi Pharm.'s global expansion and pipeline advancement.